384 results about "Binding ability" patented technology

This invention relates to a method for producing a zinc finger nucleic acid binding protein comprising preparing a zinc finger protein according design rules, varying the protein at one or more positions, and selecting variants which bind to a target nucleic acid sequence by polysome display.

The present invention is directed to methods for purifying a non-human antibody, or antigen binding portion thereof, exhibiting weak binding strength and low binding capacity for Protein A chromatography media. In one aspect, a kosmotropic salt solution is employed to promote the hydrophobic interaction between the non-human antibody, or antigen binding portion thereof, and the Protein A ligand, thereby enhancing the binding of the non-human antibody, or antigen binding portion thereof, to the Protein A chromatography media. In another aspect, the concentration of the non-human antibody, or antigen binding portion thereof, in a sample comprising the antibody, or antigen binding portion thereof, exposed to a Protein A chromatography media is increased to enhance the binding of the non-human antibody, or antigen binding portion thereof, on the Protein A chromatography media.

The present invention provides efficient methods based on alteration of the protein A-binding ability, for producing or purifying multispecific antibodies having the activity of binding to two or more types of antigens to high purity through a protein A-based purification step alone. The methods of the present invention for producing or purifying multispecific antibodies which feature altering amino acid residues of antibody heavy chain constant region and/or variable region. Multispecific antibodies with an altered protein A-binding ability, which exhibit plasma retention comparable or longer than that of human IgG1, can be efficiently prepared in high purity by introducing amino acid alterations of the present invention into antibodies.

Methods for improving the specific binding ability of bispecific binding compositions are described. The bispecific binding compositions are able to target cells by a high affinity targeting domain to a target cell surface marker and a low affinity binding domain that binds specifically to a second cell surface marker, wherein the binding of each domain to its respective cell surface marker increases or decreases, as desired, the biological activity of the respective cell surface markers. The invention further provides bispecific binding agents for use in the methods, as well as uses for the agents.

The present invention discloses a high-performance flame-proof abrasion-resisting composite material which is prepared mainly by the components of particle material alumina or/and corundum or/and mullite 50-70 parts; hard particle 5-25 parts; binding agent 8-25 parts; aluminum oxide micro powder or/and silicon micronized quartz powder 8-15 parts and surfactant 0.1 parts. The composite material is developed according to the scientific knowledge obtained in the long-term researching and producing for the flame-proof abrasion-resisting composite material in our company and absorbing the latest accomplishment of the present material science, the material has the advantages of increasing the high-temperature bonding strength and toughness of the composite material, increasing the binding ability of the interface between the composite material and the equipment, facilitating the two sides forming a compact and high-strength whole body, optimizing the capability of the composite material in the high-temperature state, prolonging the service lifetime of the equipment, reducing the number of the breakdown maintenance, reducing the material consumption and the labor intensity of the worker thereby obtaining the purpose of increasing the economic benefit of the enterprise.

The present disclosure relates generally to multi-specific Fab fusion proteins (MSFP) which comprise an antibody Fab fragment with both N-termini fused to a fusion moiety (fusion moiety A or B). MSFP containing the Fab fragment exhibit significantly reduced binding ability of the Fab fragment to the Fab target. Binding of the Fab to its target is restored when the MSFP is clustered on a cell surface by binding of the fusion moieties to their target. The reduced binding of the Fab to its target, especially when presented on a cell surface in its native state, absent fusion moiety binding provides advantages such as: reduced side effects and allows desirable pharmacological effects of selectivity and specificity in a controlled manner.

A method of purifying biomolecules with an anion exchanger containing a membrane having a surface having a polymer such as a primary or secondary amine ligand formed thereon, such as polyallylamine. The feedstock is introduced to the exchanger in the presence of one or more ionic-modifiers by themselves or in combination with monovalent salt. The ionic modifier alters the binding ability of the primary amines such that they retain a significant binding capacity for highly charged species such as DNA but lose part or almost all of their binding capacity for less charged species such as viruses or proteins at pH above the pI of the virus or protein.

Provided are an electrode for solid-state batteries, a method of preparing the electrode, a solid-state battery including the electrode, and a bonding film used for the method of preparing the electrode. The electrode for solid-state batteries include a bonding layer interposed between an electrode layer and a current collecting member and bound to the electrode layer, where the bonding layer includes a first binder which is inactive to the solid electrolyte, a second binder which has a stronger binding ability to the current collecting member than a bonding strength of the first binder to the current collecting member; and a bonding layer conductive material.

The present invention relates to monoclonal antibodies that bind or neutralize Hendra or Nipah virus. The invention provides such antibodies, fragments of such antibodies retaining Hendra or Nipah virus-binding ability, fully human antibodies retaining Hendra or Nipah virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.

The invention provides a bispecific antibody. The bispecific antibody is composed of a single brand unit and a univalent unit, wherein the single brand unit has specific binding ability on surface antigen CD3 of immune cells, and the univalent unit has specific binding ability on surface antigen EGFR of tumor cells; and the single brand unit includes a single brand variable fragment (ScFv) fused with an Fc fragment, and the univalent unit includes a light strand and heavy strand pair. The invention also provides a preparation method and a pharmaceutical use of the bispecific antibody.

Aspects of the invention relate to methods for measuring the binding constant of a lipophilic or amphiphilic molecule acceptor for a lipophilic or amphiphilic molecule. Methods involve rapid, cell-free competition assays including a labeled lipophilic or amphiphilic molecule and nanoparticle.

The invention discloses a silane-nanoceramic composite surface conditioning agent. The silane-nanoceramic composite surface conditioning agent is used for surface treatment before metal electrophoresis coating, and 1L of the composite surface conditioning agent comprises 100-100000mg of amino silane or epoxy silane, 1-10000mg of dispersible nanoparticles, 10-50000mg of a zirconium compound or a titanium compound, and the balance of water. The silane-nanoceramic composite surface conditioning agent does not contain phosphorus or other harmful elements, and has pollution to environment in the use process; and compared with present phosphorus-free surface conditioning agents allowing a treated metal to have a thin film on the surface and have poor physical bonding ability with an electrophoresis coating, the silane-nanoceramic composite surface conditioning agent allows a treated metal to have a thick film on the surface in order to enhance the physical binding ability with the electrophoresis coating, so the corrosion resistance and the throwing power of the electrophoresis coated metal are greatly improved.

Titanium oxide-antibody conjugated particles are disclosed, which are provided with selective binding ability without loss of dispersibility and catalytic activity by modifying titanium oxide conjugated particles, dispersed in a water-based solvent by a water-soluble polymer, with an antibody via a linker molecule bound without changing the nature of the water-soluble polymer. The present invention is an antitumor agent, comprising titanium oxide-antibody conjugated particles, wherein a linker molecule is bound to the titanium oxide surface of the titanium oxide conjugated particles, dispersed in a water-based solvent by a water-soluble polymer, via at least one functional group selected from a group consisting of a carboxyl group, an amino group, a diol group, a salicylic acid group, and a phosphoric acid group, and wherein the titanium oxide conjugated particles are further modified with an antibody via the linker molecule. This antitumor agent is concentrated in the affected area and can be utilized as an agent for diagnosis or for treatment in combination with ultrasonic irradiation.

The present invention relates to a anti-ultraviolet superfine polyester fibre and its preparation process characterized by that the weight composition is 98-70 parts of polyester and 2-30 parts of surface coupled anti-ultraviolet additive, the titer of the fibre is 0.3-0.7dtex, the grain size of the anti-ultraviolet additive is 20-200nm. In this invention, because the anti-ultraviolet additive is treated with coupling agent to increase the additive amount, the anti-ultraviolet superfine polyester has not only remarkable ultraviolet resistance but also better binding ability with parental material and excellent mechanical property, providing large application field and significant social and economical benefit.

Disclosed is a crystalline human CR2 protein in complex with C3d, and the three dimensional structure of the crystalline complex. Also disclosed are methods of use of the structure, particularly for structure-based identification of compounds that bind to CR2 and inhibit or enhance the binding of CR2 to a natural ligand, that bind to CR2 and agonize or antagonize the receptor, that bind to CR2 and inhibit or enhance CR2 dimerization, or that use the C3-binding ability of CR2 as a drug delivery vehicle. Also disclosed are therapeutic compounds obtained by such methods and uses for such compounds.